Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers World Congress 2019

Shannon Pendergrast's Biography

Shannon Pendergrast, Chief Scientific Officer, Ymir Genomics

Dr. Pendergrast received his PhD from the Rutgers University Waksman Institute of Microbiology in Molecular Genetics, did his post-doctoral training at Cold Spring Harbor Laboratories, and has over 12 years of experience in industry as a Scientist, Executive, and Entrepreneur. Throughout his career Dr. Pendergrast has developed cutting edge methods to further our understanding of biological processes. As a graduate fellow in the lab of Dr. Richard Ebright a post-doctoral research with Dr. Nouria Hernandez and a Senior Principal Investigator at The Archemix Corp he developed a new methods to characterize protein-nucleic acid complexes for research and drug discovery. As CSO of Ymir Genomics LLC he entered the field of Biomarker Discovery and characteristically went right to work developing innovative new methods to improve extracellular biomarker isolation from biofluids. He has published over 30 scientific papers, patents and book chapters and is an Associate Editor of the Journal of Circulating Biomarkers.

Shannon Pendergrast Image

A Novel Extracellular Vesicle Isolation Method Used to Discover Urine Liver Disease Candidate Biomarkers

Wednesday, 27 March 2019 at 16:30

Add to Calendar ▼2019-03-27 16:30:002019-03-27 17:30:00Europe/LondonA Novel Extracellular Vesicle Isolation Method Used to Discover Urine Liver Disease Candidate BiomarkersCirculating Biomarkers World Congress 2019 in Coronado Island, CaliforniaCoronado Island,

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, with increasing incidence, and is the third most common cause of cancer death. The clinical management of patients suffering from HCC, despite the fact that at-risk populations are well defined, is not satisfactory. This is mainly due to the unavailability of current diagnostics to predict and monitor the disease. OHSU and Ymir Genomics LLC have teamed up to develop a high-compliance urinary diagnostic for liver diseases, including HCC. We have developed a new method for the rapid and effective isolation of urine extracellular vesicles (EVs) and integrated that into Mass Spectrometry and miRNA array workflows. We have applied  the workflow to 3 groups of 20 urine samples each from 1) healthy controls, 2) patients with cirrhosis, and 3) and cirrhotic patients with untreated HCC. Mass Spectrometry data shows that this protocol is capable of identifying over 2500 proteins from only 2 mls of urine; far less sample than some previously reported urine EV proteomics studies. Our protocol also yields sensitive miRNA detection from the Firefly miRNA array. Preliminary data establishes proof-of-concept by identifying multiple liver-selective and known liver disease biomarkers in urine EV preps. Several candidate protein and miRNA biomarkers that are potentially capable of distinguishing disease from healthy groups have also been identified. The methods developed in this study are suitable for a larger longitudinal study, as they are already compatible with standard clinical chemistry laboratory assay requirements.  Hopefully, candidates biomarkers identified in this study will provide clinicians with powerful weapons in the fight against HCC.

Add to Calendar ▼2019-03-27 00:00:002019-03-29 00:00:00Europe/LondonCirculating Biomarkers World Congress 2019Circulating Biomarkers World Congress 2019 in Coronado Island, CaliforniaCoronado Island,